clinical trial · NCT07481981
A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)
Pulmonary Arterial HypertensionTreprostinil Palmitil Inhalation PowderPlacebo
brief summary
The primary objective of this study is to evaluate the effect of 24-weeks of once daily treatment with TPIP compared with placebo on exercise capacity in adults with PAH.
started
Apr 17, 2026
primary completion
Dec 28, 2028
completion
Jan 28, 2029
last updated
Mar 19, 2026
official title
A Phase 3, Randomized, Double-Blind, Placebo-controlled, Multicenter, Parallel-group Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol